<DOC>
	<DOCNO>NCT00903656</DOCNO>
	<brief_summary>The aim study evaluate potential Lapatinib plus Caelyx combination therapy effective safe therapeutic regimen favourable cardiotoxicity profile , treatment metastatic breast cancer follow failure prior trastuzumab .</brief_summary>
	<brief_title>Lapatinib Plus Caelyx Patients With Advanced Metastatic Breast Cancer Following Failure Trastuzumab Therapy</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Lapatinib</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<criteria>Female patient , age â‰¥ 18 year Advanced metastatic breast cancer , histologically confirm Documented HER2 overexpression ( IHC 3+ and/or FISH positive ) At least one measurable lesion accord RECIST criterion . Patients boneonly lesion eligible study entry Documented disease progression Patients may 1 line palliative treatment , however prior therapy must include trastuzumab adjuvant metastatic set Life expectancy least 12 week Performance status 01 Cardiac ejection fraction &gt; = 50 % measure echocardiogram MUGA scan Adequate hematology , liver renal function Pregnant lactate woman Serious medical psychiatric disorder would interfere patient 's safety inform consent Severe cardiac disease ( uncontrolled angina , arrhythmia , chronic heart failure ( CHF ) cardiac disease require device ) Ejection fraction institutional normal limit Maximum cumulative dose 360 mg/m2 doxorubicin 720 mg/m2 epirubicin Active bacterial , viral fungal infection Patients clinically apparent brain metastasis Positivity HIV , Hepatitis B C History malignancy ; patient diseasefree 5 year Concurrent cancer therapy ( chemotherapy , radiation therapy , immunotherapy , biologic therapy ) concurrent treatment investigational drug participation another clinical trial Known hypersensitivity study drug Lapatinib Caelyx excipients</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>metastatic breast cancer</keyword>
	<keyword>Her2</keyword>
	<keyword>Lapatinib</keyword>
	<keyword>Caelyx</keyword>
	<keyword>cardiotoxic</keyword>
</DOC>